“…Jasanoff (1990), in her case studies, provided numerous examples. This includes the choice of theoretical models in evaluating exposure pathways/harm mechanism, the preferred observation methods, the scientific models on dose-effect relationship, the subjectivity involved in counting excess tumors, the appropriate extrapolation factor from animal test to humans and the judgment involved in deciding whether observed effects in one tissue is idiosyncratic or can be generalized (for additional examples of how science and policy are socially negotiated, see Coutant (2000)). Since the research design, the chosen paradigms for ana-lyzing clinical trials results, the acceptable level of harm and what is deemed as acceptable proof are all subject to social negotiation, this suggests that the "science" behind FDA's science policy is malleable (Jasanoff, 1990).…”